



Innovate Biopharmaceuticals Targeting Celiac disease and Ulcerative Colitis, Meeting With Potential Investors, Partners During J.P. Morgan Healthcare Conference

January 4, 2017

RALEIGH, North Carolina, Jan 4, 2017 Executives From [Innovate Biopharmaceuticals, Inc.](http://www.innovatebiopharma.com) which has drug candidates entering Phase 3 and Phase 2 clinical trials, respectively, for the treatments of celiac disease and ulcerative colitis, will be in San Francisco Jan. 8-12, meeting with potential investors and partners gathered for the J.P. Morgan Healthcare Conference.

Interested investors and licensing partners can email the company to schedule one-on-one meetings during the week:
investor.relations@innovatebiopharma.com

Innovate is a privately held, clinical stage biotechnology company focused on developing novel autoimmune/inflammation medicines. Innovate is also developing therapeutics for unmet needs with global impact and for orphan indications.

The company's lead drug candidate for celiac disease, larazotide acetate (INN-202), will begin Phase 3 clinical trials in 2017. Larazotide, a novel oral peptide, has been studied in more than 800 patients with results that consistently reduced clinical symptoms of celiac disease. Larazotide's unique mechanism of action of reducing antigen trafficking across epithelial cells makes it a promising therapeutic for multiple diseases involving "leaky tight junctions."

Innovate's second therapeutic, INN-108, enters Phase 2 trials in 2017. INN-108 is a small molecule for the treatment of an adult orphan indication and for mild to moderate ulcerative colitis. INN-108 is a prodrug that only becomes activated in the colon. An oral liquid formulation is also in development for pediatric and elderly patients.

Innovate is seeking licensing partners to develop its two drug candidates outside the United States.

Forward Looking Statements

This press release contains forward-looking statements, including statements regarding the clinical development of our product candidates, which are subject to risks and uncertainties that could cause actual results to differ materially. Reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: risks associated with the success, cost and timing of our product development activities and clinical trials; the approval and commercialization of our product candidates; and risks of increased regulatory requirements, amongst others. These forward-looking statements speak only as of the date hereof. Innovate Biopharmaceuticals disclaims any obligation to update these forward-looking statements

SOURCE:Innovate Biopharmaceuticals:

Investor Relations

[Kendyle Woodard](mailto:investor.relations@innovatebiopharma.com)

Tel: +1 (919) 275 - 1933

investor.relations@innovatebiopharma.com
www.innovatebiopharma.com